Skip to main content

Drug Interactions between brimonidine topical and Zanaflex

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tiZANidine brimonidine topical

Applies to: Zanaflex (tizanidine) and brimonidine topical

MONITOR: Topically administered alpha-2 adrenergic agonists such as apraclonidine and brimonidine may potentiate the hypotensive and sedative effects of tizanidine, which is a muscle relaxant with centrally-acting alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure. In a single-dose study where blood pressure was monitored closely after dosing, two-thirds of patients treated with an 8 mg dose had a 20% reduction in either the diastolic or systolic blood pressure. The reduction was seen within 1 hour after dosing, peaked 2 to 3 hours after dosing, and was associated at times with bradycardia, orthostatic hypotension, lightheadedness, dizziness, and rarely, syncope. The hypotensive effect of tizanidine is dose-related and has been measured following single doses of 2 mg or more. Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed. Although commercially available agents are hydrophilic and do not readily distribute across the ocular-blood barrier into the central nervous system, prolonged use may increase the risk of systemic effects. There have been occasional reports of bradycardia, chest heaviness or burning, palpitation, reduced blood pressure, and orthostatic hypotension when apraclonidine 1% eyedrop was administered once or twice a day for 4 weeks to individuals not undergoing laser surgery.

MANAGEMENT: Caution is advised if tizanidine is used in combination with topical alpha-2 adrenergic agonists. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position, and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid activities requiring mental alertness until they know how these agents affect them.

References

  1. King MH, Richards DW (1990) "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol, 110, p. 308-9
  2. Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR (1990) "Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine." Arch Ophthalmol, 108, p. 1264-7
  3. "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc
  4. Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J (1995) "The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine." Arch Ophthalmol, 113, p. 77-83
  5. (2001) "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc
  6. Walters TR (1996) "Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies." Surv Ophthalmol, 41 ( Suppl, s19-26
  7. (2001) "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics
  8. Pekdemir M, Yanturali S, Karakus G (2005) "More than just an ocular solution." Emerg Med J, 22, p. 753-4
  9. (2013) "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc
View all 9 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.